November 2013; 10 years ago (2013-11), in Cambridge, Massachusetts
Founders
Jennifer Doudna
Feng Zhang
George Church
David R. Liu
J. Keith Joung
Headquarters
Cambridge, Massachusetts
,
United States
Number of locations
2
Key people
James Mullen (chairman)
Gilmore O'Neill (president and CEO)
Revenue
US$19.7 million (2022)
Operating income
US$−226 million (2022)
Net income
US$−220 million (2022)
Total assets
US$514 million (2022)
Total equity
US$361 million (2022)
Number of employees
226 (2023)
Website
editasmedicine.com
Footnotes / references [1]
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.[2][3] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.[4][5][6]
^"2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 22, 2023.
^"The week in science: 5–11 February 2016". Nature. 530 (7589). Business: CRISPR goes public. 10 Feb 2016. Bibcode:2016Natur.530..134.. doi:10.1038/530134a.
^"Editas Wins FDA Approval for IND of CRISPR Treatment for LCA10". Genetic Engineering & Biotechnology News. 30 November 2018. Retrieved 20 August 2020.
^Werley, Jensen (5 September 2019). "How Boulder biotech companies are putting Colorado on the gene-editing map". Denver Business Journal. Retrieved 27 October 2020.
^Symington, Steve (20 August 2020). "Editas Medicine Remains on Track". The Motley Fool. Retrieved 20 August 2020.
^"Who We Are". Editas Medicine. Retrieved 2022-02-25.
editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. EditasMedicine was originally founded...
its COVID-19 vaccine. In 2013, Flagship helped fund the creation of EditasMedicine to use CRISPR gene editing for the development of pharmacological therapies...
"Allergan and EditasMedicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10". EditasMedicine. Retrieved...
and invested in more than 60 companies, including Sage Therapeutics, EditasMedicine, Constellation Pharmaceuticals and Flare Therapeutics. DeAngelis, Allison...
2016. Retrieved 4 August 2020. Picker, Leslie (3 February 2016). "EditasMedicine and BeiGene Gain in Market Debuts". The New York Times. ISSN 0362-4331...
biochemical assays. Zhang, Doudna, and other colleagues from Harvard founded EditasMedicine in September 2013 to develop and commercialize CRISPR-based therapies...
better known CRISPR–Cas9 used by companies like Caribou Biosciences, EditasMedicine, Synthego, Intellia Therapeutics, CRISPR Therapeutics and Beam Therapeutics...
commercialize CRISPR technology, in 2011. In September 2013, Doudna cofounded EditasMedicine with Zhang and others despite their legal battles, but she quit in...
(páthos) 'pain, suffering'), unlike Osteopathic medicine, is a pseudoscientific system of alternative medicine that emphasizes physical manipulation of the...
treatment of various rare diseases. Mendlein is also a board member of EditasMedicine (Nasdaq: EDIT), Moderna Therapeutics and Axcella Health. He is a founder...
with 3 years of work expected before clinical trials are considered. EditasMedicine, that previously collaborated with the Cullen Lab, are researching...
commercialize CRISPR in various ways, including Caribou Biosciences, EditasMedicine, and CRISPR Therapeutics. While Doudna was involved in some of commercial...
Therapeutics CSL Behring Cytokinetics Daiichi Sankyo EditasMedicine Eli Lilly and Company Foundation Medicine Galderma Genentech GlaxoSmithKline Horizon Therapeutics...
companies that have found their way into the market, among them Agios, Editas, Rhythm, and Zafgen. Tartaglia was born in Albany, New York in 1963. In...
Målbeskrivningar 2015 (PDF). Falun, Sweden: Edita Bobergs AB. p. 521. ISBN 978-91-7555-304-7. "Critical Care Medicine | ACP Online". www.acponline.org. June...
September 1770) was a German-born Dutch anatomist. He served a professor of medicine at the University of Leiden like his father Bernhard Albinus (1653–1721)...
2024-03-28. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee to Review the...
Global Information
US$19.7 million (2022)
